Stem cell research is a promising and rapidly growing field in regenerative medicine. Stem cells are undifferentiated cells which have both the ability to self-renew for extended periods of time and to differentiate into any number of specialized cell types under the appropriate conditions. These characteristics suggest that stem cells are an optimal candidate for cell-therapy based medicine for illnesses including Parkinson's disease, diabetes, Duchenne muscular dystrophy (DMD) and heart disease. However, the specific signals which stem cells require in order to be directed to a particular lineage must be elucidated before they can be effectively used in a clinical setting. The use of small molecules to control stem cell fate will be advantageous to the advancement of stem cell biology, 1 regenerative medicine 2 and drug discovery. 3 Stem cells are typically categorized as either embryonic or adult. Embryonic stem cells are derived from the inner cell mass of the early embryonic blastocyst. The cells of the inner cell mass give rise to all three primary germ layers and germ cells of the developing embryo, therefore the cells have the potential to differentiate into a wide variety of cell types. Adult stem cells are undifferentiated cells found within differentiated tissue that typically give rise to new cells of the tissue from which they originate, though many studies have provided evidence that adult stem cells are indeed multipotent and not confined to the differentiation potential of their original tissue. 4, 5 Embryonic and adult stem cells can be harvested and grown in culture. The expansion and differentiation behavior of cells in culture is typically defined by the growth media in which the cells are grown. The media contain a cocktail of effectual molecules such as growth factors which dictate the differentiation of cells in vitro. Unfortunately, growth media are often not fully defined; they may contain factors which promote the growth of many different cell types, resulting in an inconsistent and/or heterogeneous mix of cells ( Figure 1 ). For example, it has been reported that fetal calf serum, a common additive to growth media, may contain growth factors such as bone morphogenetic protein (BMP) which can both drive neural differentiation through the leukemia inhibitory factor (LIF) pathway 6 and promote self-renewal through inhibition of extracellular signalregulated kinase/mitogen-activated protein kinase pathways. 7 Because cell-based therapies may require large quantities of stem cells for clinical use, it would be advantageous to isolate specific small molecules which either maintain self-renewal or drive tissue specific fates of stem cells.
Stem cells share many properties with cancer cells, and the idea that cancer arises from embryonic-like remnant cells in adult tissue was proposed over 150 years ago. 8 Both natural and synthetic small molecules have been shown to be useful chemical tools for manipulating the fates of cells. Small molecules are standard chemotherapeutics in the treatment of cancer. In general, these small molecules target signaling transduction pathways (for example, tyrosine kinase receptors) and affect DNA replication, tumor metastasis, and apoptosis. In addition, cell differentiation therapy for cancer is based on the idea that cancer cells are embryonic-like cells, which have become arrested in an undifferentiated state and hence continue to proliferate. Cell differentiation therapy proposes to promote the differentiation or maturation of cells. For example, all-trans retinoic acid (RA) has a role in stem cell differentiation to several lineages including myeloid differentiation. In acute promyelocytic leukemia, a chimeric protein results from the translocation mutation of the promyelocytic gene (PML) and the RA receptor gene (RAR-a, t15:17). The resultant fusion product blocks the activity of the PML protein, which is required for cell differentiation. RA and retinoids bind to the RA receptor (RAR-a) component of the fusion product, inducing its degradation and finally allowing PML to participate in granule formation and differentiation of promyelocytes; and targeted treatment with the small molecule RA treatment results in remission of 70% of patients. 9 Clearly, the similarities in stem cells and cancer cells can provide insights to control and directing cell behavior.
Small molecules are also important tools for understanding mechanistic and developmental processes. For example, it was found that the nucleodside 5-azacytidine, a DNA demethylating agent, 10 could induce myogenic, [11] [12] [13] [14] adipogenic 11, 14 and, to a lesser extent, chondrogenic 11, 14 differentiation. Although the use of 5-azacytidine is most frequently associated with myogenic differentiation, it has been associated with differentiation of cardiomyocytes, 13 hepatocytes 15 and epithelia. 16 The work of H. Weintraub, which examined the effect of 5-azacytidine on the myogenic differentiation of murine mesenchymal progenitors, 17 ultimately led to the discovery of the myogenic transcription factor, MyoD, which is considered the master regulator of myogenesis. This ability to be manipulated to a desired phenotype makes stem cells an invaluable resource in modern pharmacology. A recent review 18 highlights the use of small molecules to modulate stem cells to clinically relevant phenotypes; this allows for more accurate drug target validation and increased understanding of drug mechanisms of action.
Because of the potential of small molecules to control stem cell fates, 19 libraries of small molecules have been examined for anticancer behavior and, more recently, for stem cell self-renewal and differentiation capabilities. Strategies for generating functional small molecules of synthetic and natural product libraries, based on motifs of known ligands, have been outlined previously. [20] [21] [22] In this review, we will look at several small molecules that have been highlighted in the recent literature and have been established as effectors of stem cell self-renewal or differentiation (Table 1) .
Small molecules in Wnt signaling and stem cell self-renewal and differentiation
Self-renewal
Until recently, both murine and human embryonic stem cells (mESCs and hESCs) were routinely cultured on a layer of feeder fibroblast cells. The feeder cells conditioned the media in such a way that the stem cells cocultured with them remained undifferentiated. This was evidenced by culturing hESCs without a layer of feeder cells, but with conditioned media from mouse embryonic fibroblasts. hESCs cultured with this conditioned media expressed markers such as Oct-4, a protein involved in embryonic stem cell self-renewal, and also retained the characteristic morphology of the undifferentiated state. 31 Xu et al. 32 reported a successful feeder-free growth system for undifferentiated human embryonic stem cells in 2001. Most recently, Miyabayashi et al. 33 have shown that embryonic stem cells can be manipulated to undergo long-term expansion with the use of a single small molecule, IQ-1, which modulates their long term expansion by the Wnt/B-catenin pathway.
It has long been established that mESCs can be kept undifferentiated in culture simply by adding LIF 34 , which activates the signal transducer and activator of transcription (STAT) pathways; the activation of STAT3 appears to be both necessary and sufficient for mESC self-renewal. 31 However, signaling of the LIF/STAT pathway is not sufficient in preventing the differentiation of hESCs, which suggests an alternative route for stem cell self-renewal. Sato et al. 23 have demonstrated that Wnt signaling occurs independently of the LIF/STAT pathway in both murine and human embryonic stem cells. The Wnt family is a group of proteins identified throughout many vertebrate and invertebrate species, and is named after two homologous genes originally found in Drosophila, wg and int. The Wnt proteins are most commonly associated with embryogenesis and carcinogenesis. It consists of numerous paracrine factors Figure 1 Small molecules direct stem cell fate. Undefined small molecules in cell culture media may lead to uncontrolled and poorly understood stem cell population heterogeneity. Serum contains many undefined small molecules and peptides which can affect the behavior of stem cells. Alternatively, small molecules can be used as drugs to actively direct stem cell differentiation and self-renewal. Small molecules have also played a role in understanding developmental pathways and processes.
Small molecules in regulating stem cell fate RC Schugar et al Small molecules in regulating stem cell fate RC Schugar et al (for example, Wnt1, Wnt3a, Wnt8 and so on) which interact with the Frizzled family of transmembrane receptors. In its canonical pathway, the binding of Wnt ligands leads to the inhibition of glycogen synthase kinase-3 (GSK-3) and the subsequent release of b-catenin from the suppressor protein which normally targets b-catenin for degradation. b-catenin can then be translocated to the nucleus where it complexes with T-cell factor/lymphoid enhancer factor (TCF/LEF) and drives gene expression of c-myc, 35 fibronectin 36 and cyclin D1. 37 In this way, b-catenin/TCF transcriptional activity is dependent on Wnt signaling. Activation of the Wnt pathway results in the expression of transcription factors such as Oct-3/4 which are characteristic of maintaining an undifferentiated and pluripotent state. 23 Moreover, purified Wnt ligands promote self-renewal in hematopoietic stem cells; 38 this suggests that Wnt signaling maintains pluripotency in several types of stem cells, which makes the Wnt pathway an important target of stem cell activity.
6-bromoindirubin-3'-oxime (BIO) is a synthetic, cellpermeable molecule (a derivative of the compounds in mollusks which are responsible for the famous Tyrian purple dyes). BIO is the first pharmacological agent shown to maintain self-renewal in embryonic stem cells, 25 identified as a selective and potent inhibitor of GSK-3. In fact, analysis using co-crystal structures of BIO with GSK-3b shows that, when bound, BIO is positioned in the ATP binding domain of the enzyme. 39 Sato et al.
23
demonstrated that hESCs treated with BIO accumulated b-catenin in the nucleus. This was similar to the cells' response after culture in mouse embryonic fibroblastsconditioned media; hESCs treated with non-conditioned media did not show nuclear accumulation of b-catenin. The authors concluded that BIO activated the Wnt pathway in hESCs. Furthermore, they demonstrated that Wnt signaling is endogenously active in LIF-treated mESCs, but not in LIF-untreated cells, which suggests that Wnt signaling is downregulated as mESCs differentiate. 23 Similarly, hESCs treated with BIO maintained high Oct-3/4 expression and an undifferentiated morphology in culture. Lastly, Sato's group showed that removal of the BIO compound allows the embryonic stem cells to undergo normal differentiation. Though, BIO may play a role in differentiation; Naito et al. 24 have shown that the Wnt/b-catenin pathway has a biphasic, developmental stage-dependent role in murine embryonic stem cells. Antagonism of the pathway, using BIO during early embryoid body (EB) development, resulted in cardiogenesis, while antagonism following the formation of EBs enhanced differentiation into hematopoietic and vascular lineages. The latter was attributed to attenuated BMP signaling as has been described formerly in zebrafish. 40 Lastly, BIO has been shown to play a role in dedifferentiation; Tseng et al. 25 have recently shown that BIO can increase the proliferative ability of highly differentiated cardiomyocytes. This also demonstrates that this small molecule's proliferation inducing properties are not confined only to stem cells (Figure 2a ).
Differentiation
The Wnt pathway not only promotes the maintenance of in vitro self-renewal of the pluripotent state, it has also been shown to both promote and inhibit differentiation of several tissue types. Wnt signaling is a critical signal during embryogenesis, in part because it regulates skeletal development. The pathway has a fundamental role during chondrogenesis and chondrocyte differentiation. Wnt3a, for example, represses chondrogenesis and chondrocyte gene expression in a chondrogenic cell line, ATDC5, (a line of mESCs, Riken Cell Bank), through inhibition of GSK-3. 26 The addition of Wnt3a or small Purmorphamine is a Hedgehog pathway agonist which is known to induce osteogenesis in multipotent cells and preosteoblasts as well as in preadipocytes and myoblasts when treated with BMP4.
(c) Pam3Cys is a NF-kB agonist which binds to Toll-like receptors, inducing self-renewal of MSCs and preventing adipogenesis, chondrogenesis and osteogenesis. Curcumin, on the other hand, is a NF-kB antagonist which prevents the activation and translocation of NF-kB. Curcumin has been shown to be sufficient to promote myogenesis in myoblasts. 41 Further, the collagen type II promoter is regulated by Sox9. 42, 43 In addition to b-catenin, Twist1 is a transcription repressor produced via canonical Wnt signaling. 26 When SB216763 was added to cells with diminished Twist1 levels, the cells expressed aggrecan and collagen type II to a similar degree as did control cells (no knockdown, no GSK-3 inhibitor). This suggests that Twist1 inhibits chondrocyte gene expression. Furthermore, Twist1 has been shown to interact with and repress the p65 subunit of nuclear factor-kappa B (NF-kB), another transcription factor which is known to influence the fate of stem cells.
It has been established that Wnt is an inhibitor of neural differentiation in embryonic stem cells. 44 Ding and colleagues 20, 22 used the synthesis of small molecule libraries to identify small molecules which would induce neuronal differentiation in embryonic stem cells. TWS119, a 4,6-disubstituted pyrrolopyrimidine small molecule, binds to GSK-3b with high affinity; treatment of murine embryonic carcinoma cells and mESCs with TWS119 resulted in neuronal differentiation. Using neural crest stem cells, Lee et al. 45 sought to determine whether Wnt's role in neurogenesis is universal, or whether it is cell-type dependent. Neural crest stem cells give rise to most cell types of the peripheral nervous system in addition to several non-neural tissues. A mouse model displaying constitutively active b-catenin showed that sensory neurons were generated in areas of the embryo typically devoid of neural crest stem cell derivatives. Furthermore, Lee et al. 45 demonstrated that b-catenin deficient cells, when stimulated with Wnt1, did not generate any sensory neurons; this work suggests that the Wnt pathway, acting in a b-catenin dependant manner, promotes both migration of the neural crest stem cells and sensory neurogenesis. In the Xenopus model, neural crest stem cells that expressed Wnt8 or b-catenin, or those that were negative for GSK-3b, exhibited induction of neurogenic marker expression and downregulated BMP4 expression. 46 Also, a study using neural precursor cells demonstrated that Wnt signaling inhibits self-renewal and promotes neurogenesis. 47 Taken together, these separate studies demonstrate that Wnt signaling is dependent on the stage of development.
Not surprisingly, irregularities in the Wnt pathway have been implicated as the cause of malignancies such as tumorigenesis, osteoarthritis and neurodegenerative disorders. 48 50 showed that QS11 may be therapeutic for breast cancer as it effectively reduces the in vitro migration of the cancer cells (Figure 2a) .
The pathways discussed herein are not necessarily independent of one another. The Wnt and Hedgehog pathways, for example, intersect in the intestinal epithelium with Hedgehog-dependent induction of a specific Wnt agonist. 51 In particular, Hh signaling by the differentiated cells on the surface of the intestine inhibits the canonical Wnt pathway in the intestinal stem or progenitor cells so that they proliferate and regenerate epithelium in the tissue damaged by diseases of the gastrointestinal tract. 52 Small molecules in hedgehog signaling and stem cell self-renewal and differentiation
Self-renewal
The hedgehog gene family encodes three highly conserved, homologous signaling proteins, Sonic (Shh), Indian and Desert, all named for the phenotype of lossof-function mutants seen in drosophila. For example, Shh loss-of-function drosophila mutants exhibit tiny denticles on the embryo's surface, resembling a hedgehog. Gene studies in mice have shown a role for hedgehog proteins in the patterning of many tissues and organs including lung, bone, limb and central nervous system. 53, 54, 28 Classically, Shh ligands bind to Patched (Ptc) receptors. In the absence of Shh ligand, Ptc inhibits Smoothened protein, but when the ligand is bound, a conformational change releases the inhibition on Smoothened. This is followed by signal transduction through the activation of transcription factors. In addition to its many roles in development and cell differentiation, overexpression of hedgehog protein has been associated with many different cancers including medulloblastoma, the most common malignant pediatric brain tumor. 55 Because this disease is contributed to in part by overexpression of Shh, the use of a small molecule that would inhibit signal transduction by the Smoothened protein may provide a new cancer therapeutic. Cyclopamine, a naturally occurring small molecule, directly binds to and inhibits Smoothened. 27 However, Romer and Curran 55 suggest that Hh-Antag-691, which readily enters the brain and binds to Smoothened protein rendering it inactive, is a better candidate as it is shown to target the appropriate tissue type and is sufficient at lower concentrations than is cyclopamine (Figure 2b ). Hh-Antag-691-treated tumorbearing mice displayed both a decrease in proliferation and a moderate increase in apoptosis of tumor cells.
Differentiation
Shh in particular is expressed in the vertebrate embryo's notochord, floor plate and limb bud developmental centers. The Hedgehog signaling cascade is highly sensitive to small concentration changes in ligand. For example, Shh acts in opposition to BMP expression during pattern formation of the neural tube. 56 Moreover, Gianakopoulos et al. 57 were the first to demonstrate that the overexpression of Shh in pluripotent P19 mouse cells was sufficient to induce cardiomyogenesis. Hedgehog signaling may also be dependent on the developmental stage of its targeted cells. Treatment with cyclopamine resulted in defects in adult hematopoietic stem cell formation in zebrafish embryos; an effect which was Small molecules in regulating stem cell fate RC Schugar et al similar to zebrafish embryos that were deficient in the Hedgehog pathway. 58 It is not surprising that small changes in hedgehog signaling can have large developmental and, coincidentally, clinical effects.
Purmorphamine, a synthetic small molecule, is a Hedgehog pathway agonist that induces osteogenesis in C3H10T1/2 multipotent mesenchymal progenitor cells. 28 Misregulation of mesenchymal precursor cells' differentiation into osteoblasts has been implicated in bone-related diseases such as osteoporosis, thus purmorphamine may be a potent therapeutic agent for these diseases. Not only does this small molecule induce osteogenesis in the multipotent cells, it also has been shown to induce osteogenesis in preosteoblasts (MC3T3-E1) and, when combined with BMP4, in preadipocytes (3T3-L1) and C2C12 myoblasts (Figure 2b) . 28, 59 Treatment of C3H10T1/ 2 cells with Shh results in an increased expression of osteoblast marker alkaline phosphatase. 60, 61 Spinella-Jaegle et al. 62 also provide evidence that even short treatments of C3H10T1/2 cells with Shh is sufficient to dramatically reduce levels of adipocyte transcription factors such as peroxisome proliferator-activated receptor-g.
Wichterle et al. 63 directed differentiation of mESCs by growing them on a monolayer of stromal cells (PA6) which provided neural inductive signals giving the mESCs a midbrain character. However, treatment of these neuralized cells with the naturally occurring small molecule RA converted them to display a cervical spinal character; this supports the opinion that RA induces a spinal fate in vitro in a similar fashion as it does in the normal patterning of the neural tube in vivo. Furthermore, they showed that the generation of motor neurons by the RA-treated mESCs was dependent on Hedgehog signaling as evidenced by increased numbers of motor neurons, which corresponded to increasing concentrations of Hedgehog agonist, Hh-Ag1.3.
The diverse roles of the Hedgehog family proteins in neural development have targeted them as a potential therapeutic agent for Parkinson's disease, stroke and mechanical nerve injury. Pepinsky et al. 64 sought to improve the pharmacokinetic and dynamic properties of the Shh molecule for therapeutic use. They modified Shh by conjugating polyethylene glycol (PEG), which is known to both increase solubility and decrease renal clearance of other small peptides in vivo. Pepinsky et al. applied PEGylated Shh to a murine sciatic nerve injury and reported 1-2 day accelerated recovery of function; interestingly, mice treated with PEGylated Shh also exhibited greater muscle mass.
Finally, in another example of pathway overlap, the overexpression of Shh in pancreatic cancer is believed to be due in part to NF-kB activity. 65 NF-kB-induced Shh expression enhanced cell proliferation in pancreatic cancer cells, though the direct mechanism is not fully understood. A small molecule inhibitor which would interfere with this pathway may present an effective therapeutic for decelerating the rate of cancer cell growth in the pancreas.
Small molecules in NF-jB pathways and stem cell self-renewal and differentiation
Self-renewal
NF-kB's myriad roles in regulation of biological functions have been demonstrated in embryonic development, the development and physiology of tissues and its critical role in the immune system. 66 The NF-kB protein family is one of the most studied of eukaryotic transcription factors and has been shown to be involved in many cellular processes including response to immune or inflammatory stimuli, cell growth and apoptosis. Not surprisingly, NF-kB has been associated with diseases such as cancer, rheumatoid arthritis, sepsis and asthma.
In the canonical pathway, NF-kB is inactive and sequestered in the cytoplasm by IkB proteins. The binding of tumor necrosis factor-a (TNF-a) to its receptors signals the recruitment of the IkB Kinase complex (IKK) which phosphorylates both IkB and NFkB. 64 Phosphorylated IkB is targeted for ubiquitination and degradation, while phosphorylated NF-kB is rendered active and translocated to the nucleus where it targets genes for transcription. 67 There are numerous published gene targets of NF-kB including TNF-a, 68, 69 
BMP4
70 and fibroblast growth factor 8 (FGF8), 71 all of which play a role in cellular differentiation. Therefore, the development of small molecules which can manipulate the NF-kB pathway and the transcription of these genes may aid in driving stem cells to a desired fate.
Differentiation
Recently, Panepucci et al. 72 have shown that CD34+ hematopoietic stem and progenitor cells (HSPCs) derived from the umbilical cord blood overrepresent a number of NF-kB pathway components including TNF and FGF receptors, and transcription targets such as interleukin (IL)-8 and Notch1. HPSCs derived from bone marrow require exogenous stimulation by TNF in order to differentiate into T cells; however, TNF gene expression in umbilical cord blood-derived HPSCs is significantly higher than it is in BM-derived progenitors. The ability of umbilical cord blood-derived HSPCs to differentiate into T cells without prestimulation suggests that NF-kB plays a role in lymphocyte differentiation. Shojaei et al. 73 suggest that, not only are elevated NF-kB levels related to a more primitive state of HSPCs, but that they may aid in developing the immune system. According to Acharyya et al., 74 NF-kB signaling has been shown to be persistently elevated in immune cells of patients with DMD. Using the mdx mouse model of DMD, they showed that the heterozygous deletion of the NF-kB p65 subunit was sufficient to improve pathology of the disease. They speculate that chronic NF-kB signaling is responsible for the persistent immune response in dystrophic muscle and also the repression of differentiation to regenerate new muscle fibers. Guttridge et al. 75 previously showed that TNF-induced NF-kB activation suppressed MyoD mRNA, thus inhibiting skeletal muscle differentiation. Along these lines, Mourkioti et al. 76 demonstrated that depleting IKK2 in mouse models of muscle injury and atrophy resulted in muscle with increased strength, greater muscle force and longer endurance, which suggests that there is a link between muscle repair and NF-kB inhibition. A promising treatment for DMD is cell-based therapy whereby transplanted stem cells fuse with host fibers to give rise to new dystrophin-positive fibers in the DMD mdx host which is normally lacking in dystrophin expression. 77 Therefore, pharmacological inhibition of the NF-kB pathway could be useful in both promoting Small molecules in regulating stem cell fate RC Schugar et al muscle differentiation and decreasing inflammatory responses, making it a critical target of clinical investigation.
Small molecules have been used to target the NF-kB pathway of mesenchymal stem cells (MSCs). PevsnerFischer et al. 29 reported that adult MSCs express Toll-like receptors which, upon binding of ligand, stimulate the secretion of IL-6; in turn, IL-6 induces NF-kB translocation to the cytoplasm for gene transcription. Pam3Cys, a synthetic Toll-like receptor ligand, inhibited MSC differentiation into chondrocytes, osteocytes and adipocytes when added to the proper induction media. MSCs demonstrated a four-fold increase in nuclear NF-kB protein levels only 15 min after adding Pam3Cys to the proliferation media. Furthermore, the addition of Pam3Cys to media resulted in increased MSC proliferation and decreased basal motility. The authors propose that NF-kB activation promotes MSC proliferation and inhibits differentiation; perhaps activation through Tolllike receptors provides a means of promoting selfrenewal of these stem cells. However, curcumin, a naturally occurring polyphenol, was shown to both block the activity of NF-kB (by inhibiting phosphorylation of IkB) and increase expression of embryonic myosin heavy chain when systemically delivered to muscle postinjury. 78 The authors conclude that NF-kB inhibition in myoblasts is sufficient to stimulate differentiation into muscle in a mouse model (Figure 2c) . 78 Most recently, the vast role of Toll-like receptors has been analyzed for its potency in immune and inflammatory responses and numerous agonists and antagonists of the receptors have been identified as effectors of specific fates. Kanzler et al. 79 recently compiled more than 40 compounds that act on Toll-like receptors that are in clinical trials for treatment of certain cancers, such as breast cancer and melanoma; allergies to ragweed, dust mites and asthma; and infectious diseases, such as HIV and Hepatitis C. NF-kB is known for its role in controlling apoptosis, so it comes as no surprise that the transcription factor is involved in the development of certain cancer types. Constitutive activation of NF-kB is linked to malignancies such as multiple myeloma, chronic lymphocytic leukemia and several lymphomas; 30 therefore, small molecules which can modulate NF-kB activity may be potent therapeutics for certain cancers. Habens et al. 30 demonstrate the effectiveness of sulfasalazine (SFZ) a synthetic small molecule, as an inhibitor of IKK, which also results in the inhibition of NF-kB and subsequent apoptosis. Additionally, they showed that certain SFZ analogues produced compounds that are even more highly effective in inducing apoptosis in chronic lymphocytic leukemia cells in vitro.
Small molecule therapy in regenerative medicine requires an interdisciplinary approach
The use of small molecules to direct the fate of stem cells will allow for the controlled approach which is necessary for cell therapeutics. Clearly the field is interdisciplinary and involves chemists, a range of biologists and bioinformaticians. The elucidation of pathways such as those described here provides small molecule chemists with targets for control of the behavior of stem cells. While chemists build small molecule libraries which are based on the structural motifs of known ligands and regulators in specific pathways, stem cell biologists work to better understand the molecular interactions which yield specific stem cell activities.
Indeed, the recent work of Peterson et al. 80 illustrates how these fields work together. Large-scale screenings of libraries of small molecules that disrupt developmental events were used to elucidate genetic mutations which in turn, helped to bring to light previously unknown pathway mechanisms. Peterson et al. 81 applied small molecules to zebrafish embryos at the 8-16 cell stage to produce phenotypes characteristic of previously known mutations. For example, they found a synthetic molecule, 31J6, which produced a phenotype resembling both the human cardiovascular condition second-degree atrioventricular heart block and the mutant zebrafish breakdance. A normal, healthy heart has a 1:1 atrial to ventricular beat, which prevents backflow into the ventricle. Patients with atrioventricular heart block and the breakdance mutant exhibit a 2:1 ratio as do the zebrafish embryos treated with 31J6. Thus, the development of small molecules which disrupt development with the specificity of genetic mutations provides insight into developmental processes at the molecular level as well as information to link genes to their functions. 80 Furthermore, the use of small molecules provides an advantage over using genetic mutant organisms in research because they can be added or removed at any point during development whereas mutations tend to persist throughout the organism's life. Such temporal control is crucial in understanding the specific timing of developmental processes. 82 Also, the use of small molecules could prove more cost-effective than the generation of mutant animal models.
Informatics is also crucial in developing small molecule tools. The identification of thousands of proteins through the human genome project has opened the doors for new small-molecule targets which could lead to the development of new medicines to treat disease. In recent years, the National Institutes of Health has also made investments in molecular library screening. As part of the NIH's Molecular Libraries Roadmap Initiative, PubChem was released in 2004 as a searchable database of chemical structures of small organic molecules and information on their biological activities. In 2005, it formed a network of Molecular Libraries Screening Centers which use high-throughput screening methods to identify small molecules and deposit the structural and functional information into the PubChem public database. Interestingly, several biotechnology and chemical companies are now contributing small molecule structures and biological assay data (http://pubchem.ncbi.nlm.nih.gov/pcnews.html). The informatics capabilities of such public databases provide researchers with new tools to understand stem cell function and potentially control activity.
Concluding remarks
Small molecules are important tools for controlling stem cell fate as well as understanding mechanistic and developmental processes. We have only begun to touch Small molecules in regulating stem cell fate RC Schugar et al on the large influence natural and synthetic small molecules have and will continue to have on stem cell activity. The Wnt, Hegdehog and NF-kB pathways are just a few examples of pathways with significant developmental and regenerative influence which are affected by small molecules. Because of the current challenge in stem cell biology to direct stem cell behavior, small molecule chemistry and screens for libraries of small molecules has emerged as an important tool to identify drugs which can direct stem cell activity. Targets in the Wnt, Hedgehog and FGF pathways have already been useful in the treatment of cancer. As differentiation pathways are elucidated, we expect that the field of cell therapeutics and regenerative medicine will also experience exciting advancements.
